Expert Interview
Discussing Avadel's LUMRYZ (sodium oxybate) for the Treatment of Narcolepsy with a Prescriber
Ticker(s): AVDL, JAZZInstitution: University of Minnesota
- Professor and the Division Head of Sleep Medicine in the Department of Neurology & Director of the Sleep Performance Program at University of Minneosota.
- Manages about 120 patients with narcolepsy (80 of them with Narcolepsy Type 1, 40 with Narcolepsy Type 2)
- Research focuses on the development of novel treatments in sleep medicine and is NIH funded researcher in sleep.
Roughly how many patients do you currently manage with narcolepsy?
Added By: kyle_adminHave you prescribed LUMRYZ (sodium oxybate) for narcolepsy? (Rough # of patients?)
Added By: kyle_adminAre you getting asked about Lumryz by patients? Do you see the word getting out about the new once nightly option or does it only come up at patient's scheduled consultations?
Added By: user7d840d5dIn terms of coverage, how difficult is it to get a patient on Lumryz? Are there patterns emerging?
Added By: user7d840d5dCan you talk about how you (and possibly your colleagues), see the growth in use of Lumryz?
Added By: user7d840d5dOrexin antagonists are still a ways off, but how do you see them possibly changing the treatment landscape?
Added By: user7d840d5dAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
